Ivax Glucovance ANDA Approved; Inventory Build-Up Underway
This article was originally published in The Pink Sheet Daily
Executive Summary
The company holds first-to-file rights for generic of Bristol's antidiabetic, which lost marketing exclusivity Jan. 31.
You may also be interested in...
Glucovance Generics Launch
Ivax launched its generic version of Bristol-Myers Squibb's Glucovance (glyburide/metformin) May 4, triggering 180 days of marketing exclusivity
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.